{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:27:24Z","timestamp":1780986444308,"version":"3.54.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Obstructive hypertrophic cardiomyopathy (HCM) is a cardiovascular disorder characterized by significant symptom burden. This study aims to evaluate the net clinical benefit of mavacamten (a first-in-class cardiac myosin inhibitor) \u00b1 beta-blockers\/calcium channel blockers (BB\/CCBs) compared to BB\/CCB monotherapy for Chinese patients with obstructive HCM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A five-state Markov model (NYHA classes I\u2013IV and death) was developed from a Chinese healthcare system perspective. Patients were initialised in NYHA II or III states, mirroring the baseline distribution in the EXPLORER-CN trial (NCT05174416). State transitions were simulated using cycle-specific probabilities derived from trial data and validated extrapolation assumptions. All-cause mortality risks incorporated disease-specific and extra surgical mortality rates. Treatment sequencing rules reflected escalation pathways (e.g., non-response, adverse events, or eligibility for septural reduction therapy [SRT]), informed by Chinese clinical practice. Health utilities were mapped algorithmically from EXPLORER-CN patient-level EQ-5D responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over a lifetime horizon, mavacamten \u00b1 BB\/CCBs demonstrated superior health outcomes versus BB\/CCB monotherapy, with incremental gains in life-years (15.76 vs. 14.40) and quality-adjusted life-years (QALYs: 13.69 vs. 11.38).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Mavacamten provides substantial health benefits for Chinese obstructive HCM patients, including clinically meaningful improvements in survival and quality-of-life metrics relative to standard care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1636732","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:25:17Z","timestamp":1761891917000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Net health benefit of mavacamten for the treatment of Chinese patients with obstructive hypertrophic cardiomyopathy: a model-based economic evaluation"],"prefix":"10.3389","volume":"16","author":[{"given":"Han","family":"Bao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2025.04.004","article-title":"Clinical management and healthcare resource utilization among patients with obstructive hypertrophic cardiomyopathy in Spain: a real-world study","author":"Barriales-Villa","year":"2025","journal-title":"Rev. Esp. Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3750879","DOI":"10.1155\/2018\/3750879","article-title":"Disparities in the diagnosis of hypertrophic obstructive cardiomyopathy: a narrative review of current literature","volume":"2018","author":"Burns","year":"2018","journal-title":"Cardiol. Res. Pract."},{"key":"B3","article-title":"Quantifying health related quality of life benefits from patients treated with mavacamten for obstructive hypertrophic cardiomyopathy (HCM) in China based on the EXPLORER-CN trial","author":"Cheah","year":"2024","journal-title":"ISPOR Eur."},{"key":"B4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ahj.2021.05.007","article-title":"Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy","volume":"239","author":"Desai","year":"2021","journal-title":"Am. Heart J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.clinthera.2021.11.006","article-title":"Projecting the long-term clinical value of mavacamten for the treatment of obstructive hypertrophic cardiomyopathy in the United States: an assessment of net health benefit","volume":"44","author":"Desai","year":"2022","journal-title":"Clin. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40273-018-0755-x","article-title":"Evaluating cost-effectiveness models for pharmacologic interventions in adults with heart failure: a systematic literature review","volume":"37","author":"Di Tanna","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1093\/eurheartj\/ehae579","article-title":"Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Garcia-Pavia","year":"2024","journal-title":"Eur. Heart J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3760\/cma.j.issn.1673-4904.2018.02.011","article-title":"An analysis on clinical characteristics and prognosis of obstructive and non-obstructive hypertrophic cardiomyopathy","volume":"41","author":"Li","year":"2018","journal-title":"Chin. J. Postgrad. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jval.2016.11.016","article-title":"Estimating an EQ-5D-5L value set for China","volume":"20","author":"Luo","year":"2017","journal-title":"Value Health"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.jacc.2016.01.023","article-title":"Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy","volume":"67","author":"Maron","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jchf.2017.09.011","article-title":"Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy","volume":"6","author":"Maron","year":"2018","journal-title":"JACC Heart Fail."},{"key":"B12","unstructured":"The national mortality statistics by age and gender\n          \n          \n          2021"},{"key":"B13","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1161\/CIR.0000000000000937","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"B15","first-page":"3","article-title":"Mavacamten (camzyos) CADTH reimbursement recommendation","volume-title":"Canadian J. Health Technol","year":"2023"},{"key":"B16","first-page":"1","article-title":"National center for cardiovascular diseases; cardiovascular precision medicine branch of China international exchange and promotive association for medical and health care. 2023 guideline for diagnosis and treatment of patients with hypertrophic cardiomyopathy","volume":"38","year":"2023","journal-title":"Chin. Circulation J."},{"key":"B17","unstructured":"TA696: tafamidis for treating transthyretin amyloidosis with cardiomyopathy\n          \n          \n          2021"},{"key":"B18","unstructured":"TA913: mavacamten for symptomatic obstructive hypertrophic cardiomyopathy\n          \n          \n          2023"},{"key":"B19","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1001\/jamacardio.2023.3030","article-title":"Effect of mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: the EXPLORER-CN randomized clinical trial","volume":"8","author":"Tian","year":"2023","journal-title":"JAMA Cardiol."},{"key":"B20","article-title":"Patient characteristic, treatment pattern and healthcare resource utilisation of obstructive hypertrophic cardiomyopathy (HCM) in China on a cardiologist survey","volume-title":"ISPOR Europe 2024","author":"Tian","year":"2024"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1080\/13696998.2023.2277076","article-title":"Cardiovascular outcomes by time-varying New York heart association class among patients with obstructive hypertrophic cardiomyopathy: a retrospective cohort study","volume":"26","author":"Wang","year":"2023","journal-title":"J. Med. Econ."},{"key":"B22","article-title":"Mavacamten for hypertrophic cardiomyopathy: effectiveness and value; final evidence report and meeting summary","author":"Wasfy","year":"2021","journal-title":"Inst. Clin. Econ. Rev."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1636732\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:25:21Z","timestamp":1761891921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1636732\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":22,"alternative-id":["10.3389\/fphar.2025.1636732"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1636732","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"article-number":"1636732"}}